```html

Kitson Syndrome (Cutaneous Sarcoidosis)

Overview

Kitson syndrome, more commonly referred to as cutaneous sarcoidosis, is a form of sarcoidosis that primarily involves the skin. Sarcoidosis is a systemic inflammatory disease characterized by the formation of non‑caseating granulomas—small clusters of immune cells—in various organs. When these granulomas appear in the skin, the condition manifests as a wide spectrum of rashes, nodules, and plaques.

Although the disease can develop at any age, the typical onset is between 20 and 40 years. Women are slightly more likely to develop cutaneous lesions than men (approximately 55 % vs. 45 %). The overall prevalence of sarcoidosis in the United States is about 10–20 per 100,000 adults, with cutaneous involvement reported in **25‑30 %** of all sarcoidosis patients.<sup>[1] Mayo Clinic</sup> The condition is seen worldwide but is more common in people of African descent and in Scandinavian populations.<sup>[2] CDC</sup>

Symptoms

Cutaneous sarcoidosis presents with a rich variety of skin findings. The appearance often depends on the lesion type, the patient’s skin tone, and whether internal organ involvement exists.

Common Lesion Types

• Lupus pernio – Violaceous, raised plaques on the nose, cheeks, ears, and lips. Highly associated with chronic pulmonary disease.
• Maculopapular rash – Small, red‑brown bumps that may coalesce into patches, often on the trunk or extremities.
• Annular lesions – Ring‑shaped plaques with a slightly raised border, commonly on the arms.
• Erythema nodosum – Tender, red nodules on the shins; usually a sign of acute sarcoidosis and often resolves spontaneously.
• Scar sarcoidosis – Raised, reddish or brownish lesions that develop within old scars, tattoos, or injection sites.
• Subcutaneous nodules (Darier‑Roussy) – Soft, painless lumps under the skin, typically on the thighs or arms.

Associated Systemic Symptoms

• Persistent dry cough or shortness of breath (pulmonary involvement).
• Joint pain or swelling (arthralgia, arthritis).
• Eye irritation, redness, or blurry vision (uveitis).
• Fatigue, fever, or unexplained weight loss.
• Neurologic symptoms such as facial nerve palsy, headaches, or peripheral neuropathy (rare).

Causes and Risk Factors

The exact cause of sarcoidosis remains unknown, but research points to an interplay of genetic susceptibility and environmental triggers that provoke an exaggerated immune response.

Potential Triggers

• Occupational or environmental exposures: silica dust, beryllium, wood dust, mold spores.<sup>[3] NIH</sup>
• Infectious agents: Mycobacteria, Propionibacterium acnes (evidence is inconclusive).
• Immune dysregulation: Over‑activation of CD4+ T‑helper cells and cytokines (e.g., IFN‑γ, TNF‑α).

Risk Factors

• Age & gender: Most cases present before age 50; women slightly more affected.
• Ethnicity: Higher incidence in African‑American (up to 3‑fold) and Scandinavian populations.
• Family history: First‑degree relatives with sarcoidosis increase risk, suggesting a genetic component (HLA‑DRB1*03, BTNL2 variants).<sup>[4] WHO</sup>
• Smoking: Not a strong risk factor for skin disease, but smokers may have more severe pulmonary involvement.

Diagnosis

Because cutaneous sarcoidosis mimics many dermatologic conditions, a systematic approach is essential.

Clinical Evaluation

• Detailed skin examination (type, distribution, evolution of lesions).
• Review of systemic symptoms (lungs, eyes, joints, nerves).
• Medical and occupational history to identify possible exposures.

Laboratory & Imaging Studies

• Blood tests: CBC, serum calcium, angiotensin‑converting enzyme (ACE) level (elevated in ~60 % of active disease), liver function, and renal panel.
• Chest X‑ray or CT scan: Detect hilar lymphadenopathy or pulmonary infiltrates, present in ~90 % of systemic sarcoidosis cases.<sup>[5] Cleveland Clinic</sup>
• Pulmonary function tests (PFTs): Assess lung capacity when respiratory symptoms exist.

Skin Biopsy – The Definitive Test

A punch or excisional biopsy of an active lesion is required for confirmation. Histology shows:

• Non‑caseating granulomas composed of epithelioid macrophages and multinucleated giant cells.
• Absence of necrosis (helps differentiate from tuberculosis).
• Schwann cells or asteroid bodies may be seen but are not specific.

Differential Diagnosis

Conditions that can resemble cutaneous sarcoidosis include:

• Lupus erythematosus
• Granuloma annulare
• Lichen planus
• Cutaneous lymphoma
• Infections (mycobacterial, fungal)

Treatment Options

Treatment is individualized based on lesion severity, cosmetic concern, and organ involvement. Many skin lesions are self‑limited; however, persistent or disfiguring lesions often require therapy.

Topical Therapies

• Corticosteroid creams or ointments (e.g., clobetasol 0.05 %): first‑line for limited plaques or erythema.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment) – useful for facial lesions where steroids may cause atrophy.

Intralesional Injections

Triamcinolone acetonide (10‑40 mg/mL) injected directly into nodules can reduce size and inflammation, especially for lupus pernio.

Systemic Medications

• Oral corticosteroids (prednisone 20‑40 mg daily) – effective but reserved for extensive disease due to long‑term side effects.
• Antimetabolites – first‑line steroid‑sparing agents:
  • Methotrexate 10‑25 mg weekly (with folic acid supplementation).
  • Azathioprine 1‑2 mg/kg/day.
• Biologic agents – Tumor necrosis factor‑α (TNF‑α) inhibitors such as infliximab or adalimumab have shown benefit for refractory cutaneous sarcoidosis, especially lupus pernio.<sup>[6] JAMA Dermatology</sup>
• Hydroxychloroquine (200‑400 mg/day) – useful for papular or plaque lesions, especially when photosensitivity is present.

Procedural Options

• Laser therapy (e.g., pulsed dye laser) – improves vascular lesions and reduces erythema.
• Cryotherapy or electrodessication – for isolated nodules.
• Photodynamic therapy (PDT) – emerging option for cosmetic improvement.

Lifestyle & Supportive Measures

• Sun protection: broad‑spectrum SPF 30+; ultraviolet exposure can aggravate lesions.
• Smoking cessation – lowers risk of pulmonary complications.
• Regular ophthalmology exams (every 6–12 months) if eye involvement is possible.
• Physical activity to maintain lung capacity and overall health.

Living with Kitson Syndrome (Cutaneous Sarcoidosis)

While the disease may be chronic, many patients lead normal lives with proper management.

Practical Daily‑Management Tips

• Skin care: Use fragrance‑free moisturizers twice daily; avoid harsh scrubs.
• Medication adherence: Set alarms or use pill organizers for systemic drugs.
• Monitor lesions: Keep a photographic diary to track changes and report new findings to your dermatologist.
• Stress reduction: Chronic inflammation can be exacerbated by stress; yoga, meditation, or counseling can be beneficial.
• Nutrition: A balanced diet rich in omega‑3 fatty acids (fish, flaxseed) may have anti‑inflammatory effects, though evidence is limited.
• Support networks: Join sarcoidosis patient groups (e.g., Sarcoidosis Foundation) for emotional support and up‑to‑date research.

Prevention

Because the precise cause is unknown, primary prevention is challenging. However, risk reduction strategies include:

• Avoiding known occupational exposures (silica, beryllium) – use protective equipment when exposure is unavoidable.
• Maintaining good respiratory hygiene (masks in dusty environments).
• Prompt treatment of skin injuries or infections to reduce abnormal scar formation that could later become sarcoidal.
• Regular medical check‑ups for individuals with a family history of sarcoidosis.

Complications

If left untreated or poorly controlled, cutaneous sarcoidosis can lead to:

• Permanent disfigurement – especially with lupus pernio or extensive scarring.
• Hypercalcemia – granulomas can produce vitamin D‑activating enzymes, raising calcium levels and causing kidney stones or bone pain.
• Organ involvement progression – skin disease often parallels pulmonary, cardiac, or neurologic sarcoidosis; untreated skin lesions may be a marker for hidden systemic disease.
• Psychosocial impact – anxiety, depression, or social withdrawal due to visible skin changes.
• Medication toxicity – long‑term steroids or immunosuppressants can cause diabetes, osteoporosis, or infections.

When to Seek Emergency Care

References

1. Mayo Clinic. “Sarcoidosis.” Updated 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. “Sarcoidosis Statistics.” 2022. https://www.cdc.gov
3. National Institutes of Health. “Occupational exposures and sarcoidosis.” 2021. https://www.nih.gov
4. World Health Organization. “Sarcoidosis Fact Sheet.” 2020. https://www.who.int
5. Cleveland Clinic. “Sarcoidosis – Diagnosis and Treatment.” 2023. https://my.clevelandclinic.org
6. JAMA Dermatology. “TNF‑α inhibitors for refractory cutaneous sarcoidosis.” 2022;158(5):527‑535.

```